22:38 , Jun 13, 2018 |  BC Extra  |  Company News

Management tracks: Salk Institute, Galectin

The Board of Trustees for the Salk Institute for Biological Studies (La Jolla, Calif.) said that cancer and gene therapy researcher Inder Verma has resigned. The institute had placed Verma on administrative leave in April...
17:33 , Mar 2, 2018 |  BC Week In Review  |  Financial News

Finch Therapeutics raises $36 million series B round

Finch Therapeutics Group Inc. (Somerville, Mass.) raised $36 million on March 1 in an oversubscribed series B round from Shumway Capital, Willett Advisors, Morgan Noble and Avenir Growth Capital. The original target was $30 million....
16:24 , Mar 1, 2018 |  BC Extra  |  Financial News

Finch Therapeutics raises $36M series B round

Finch Therapeutics Group Inc. (Somerville, Mass.) raised $36 million in an oversubscribed series B round from Shumway Capital, Willett Advisors, Morgan Noble and Avenir Growth Capital. The original target was $30 million. CEO Mark Smith...
23:54 , Jan 4, 2018 |  BC Extra  |  Company News

Management tracks: Acceleron, Selecta

Acceleron Pharma Inc. (NASDAQ:XLRN) said EVP and CMO Matthew Sherman will retire after the company reports top-line data mid-year from the Phase III MEDALIST and BELIEVE trials of luspatercept (ACE-536) to treat lower-risk myelodysplastic syndromes...
18:59 , Oct 27, 2017 |  BC Week In Review  |  Company News

Microbiome companies Finch and Crestovo merge

Microbiome companies Crestovo LLC (Cambridge, Mass.) and Finch Therapeutics Inc. (Somerville, Mass.) merged to form Finch Therapeutics Group (Somerville, Mass.), which will focus on developing oral alternatives to fecal microbiota transplant. Crestovo's lead candidate, CP101...
22:50 , Oct 23, 2017 |  BC Extra  |  Company News

Microbiome companies Finch and Crestovo merge

Microbiome companies Crestovo LLC (Cambridge, Mass.) and Finch Therapeutics Inc. (Somerville, Mass.) merged to form Finch Therapeutics Group (Somerville, Mass.), which will focus on developing oral alternatives to fecal microbiota transplant. Crestovo's lead candidate, CP101...
21:43 , Jul 28, 2017 |  BioCentury  |  Emerging Company Profile

Microbiotal reverse-engineering

Finch Therapeutics Inc. is developing an oral alternative to fecal microbial transplant that it believes entails less biology risk than more advanced oral candidates, with more targeted delivery than full microbiome transplants delivered via enema....
20:02 , Apr 7, 2017 |  BC Week In Review  |  Company News

Finch, Takeda deal

Finch granted Takeda exclusive, worldwide rights to develop and commercialize FIN-524 and follow-on products to treat inflammatory bowel disease (IBD). Finch will receive $10 million up front and is eligible for milestones and tiered royalties....